Cargando…

Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report

BACKGROUND: PARP inhibitors have been approved as targeted therapy for BRCA-deficient metastatic ovarian cancer (OC). Fanconi anemia complementation group A (FANCA), one of the homologous recombination repair pathway genes, is a susceptibility gene to breast cancer and OC. Therefore, it is interesti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qian, Bing, Leng, Wenshu, Yan, Zhengqing, Lu, Jin, Chen, Shiqing, Yi, Huan, Jiang, Zhi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913585/ https://www.ncbi.nlm.nih.gov/pubmed/35280757 http://dx.doi.org/10.3389/fonc.2022.778545

Ejemplares similares

A Multiple Primary Malignancy Patient With FANCA Gene Mutation: A Case Report and Literature Review
por: Xia, Qing, et al.
Publicado: (2020)

A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents
por: Wilkes, David C., et al.
Publicado: (2017)

Rare variants in FANCA induce premature ovarian insufficiency
por: Yang, Xi, et al.
Publicado: (2019)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
por: Jiang, Yifan, et al.
Publicado: (2020)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
por: You, Yan, et al.
Publicado: (2020)

Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
por: Bonadio, Renata Colombo, et al.
Publicado: (2021)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
por: Bian, Yuan, et al.
Publicado: (2022)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
por: Huang, Xuan-zhang, et al.
Publicado: (2020)

Combined treatment of disulfiram with PARP inhibitors suppresses ovarian cancer
por: Tang, Bin, et al.
Publicado: (2023)

FANCA Gene Mutations in North African Fanconi Anemia Patients
por: Ben Haj Ali, Abir, et al.
Publicado: (2021)

A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer
por: Thompson, Ella, et al.
Publicado: (2005)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2022)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
por: Zuo, Wei-Wei, et al.
Publicado: (2023)

Coregulation of FANCA and BRCA1 in human cells
por: Haitjema, Anneke, et al.
Publicado: (2014)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
por: Franzese, Elisena, et al.
Publicado: (2020)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
por: Sahnane, Nora, et al.
Publicado: (2020)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

What predicts the clinical benefits of PARP inhibitors in platinum-sensitive recurrent ovarian cancer: A real-world single-center retrospective cohort study from China
por: Zhang, Depu, et al.
Publicado: (2022)

Investigation of FANCA gene in Fanconi anaemia patients in Iran
por: Saffar Moghadam, Ali Akbar, et al.
Publicado: (2016)

Radiopharmaceuticals for Relapsed or Refractory Ovarian Cancers
por: Kunos, Charles A., et al.
Publicado: (2019)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021)

Hypomorphic FANCA mutations correlate with mild mitochondrial and clinical phenotype in Fanconi anemia
por: Bottega, Roberta, et al.
Publicado: (2018)

Structural basis of the fanconi anemia-associated mutations within the FANCA and FANCG complex
por: Jeong, Eunyoung, et al.
Publicado: (2020)

Germline Mutations of Inhibins in Early-Onset Ovarian Epithelial Tumors
por: Tournier, Isabelle, et al.
Publicado: (2014)

Germline mutations in Thai patients with nonmucinous epithelial ovarian cancer
por: Manchana, Tarinee, et al.
Publicado: (2019)

FANCA Polymorphism Is Associated with the Rate of Proliferation in Uterine Leiomyoma in Korea
por: Ha, Eunyoung, et al.
Publicado: (2020)

Fanca deficiency is associated with alterations in osteoclastogenesis that are rescued by TNFα
por: Oppezzo, Alessia, et al.
Publicado: (2023)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

FANCA Gene Mutations with 8 Novel Molecular Changes in Indian Fanconi Anemia Patients
por: Solanki, Avani, et al.
Publicado: (2016)

Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?
por: Fountzilas, Elena, et al.
Publicado: (2021)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Landscape of germline BRCA1/BRCA2 variants in breast and ovarian cancer in Peru
por: Ferreyra, Yomali, et al.
Publicado: (2023)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
por: Wang, Yizi, et al.
Publicado: (2020)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
por: Ren, Ning, et al.
Publicado: (2021)

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades
por: Wang, Xiaoyan, et al.
Publicado: (2021)

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
por: Gien, Lilian T., et al.
Publicado: (2010)

PARP-1 may be involved in angiogenesis in epithelial ovarian cancer
por: Wei, Wei, et al.
Publicado: (2016)

Treatment of FANCA Cells with Resveratrol and N-Acetylcysteine: A Comparative Study
por: Columbaro, Marta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4g5qros6mg8sp1c1ijc0s06v97